Topic: management changes
Merck & Co. boasted some major sales success this year, but the company’s commercial organization will still get a makeover for 2019.
AbbVie CFO Bill Chase will retire in 2019 after helming finance since the company's birth in 2013. He'll be replaced by controller Robert Michael.
Hours after Pfizer unveiled its CEO succession plan, industry watchers had one key question: Will incoming chief Albert Bourla chase M&A?
After steering Pfizer through nine years of selloffs, spinoffs, reorgs, drug launches, patent losses, dealmaking—and one big deal that didn’t—CEO Ian Read is stepping aside.
Bayer’s Americas pharma leader is heading off to biotech, but the German drugmaker has a seasoned veteran ready to step up.
More turnover is coming to Allergan’s board—and this time, it’s the man who arguably built the company.
Gilead has some big commercial challenges looming, and it’s poached an Amgen executive to spearhead them.
Bristol-Myers Squibb has picked its new commercial chief—and the person who'll be charged with maximizing Opdivo's potential.
Bristol-Myers Squibb is locked in some pretty big marketing battles—but it’ll have to soldier on without its commercial leader.
Teva’s cost-cutting drive hasn’t been popular with workers or its home country of Israel. Analysts, on the other hand, like what they’ve seen.